CytoCore Plans Major Presence at American College of Obstetricians and Gynecologists Annual Clinical Meeting.- Official U.S. Launch of SoftPAP([R]) Collector - -New Sales Tools Unveiled- CHICAGO -- CytoCore Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :CYOE), the developer of cost-effective, highly accurate screening systems for early detection of gynecological gynecological /gy·ne·co·log·i·cal/ (-kah-loj´i-k'l) gynecologic. cancers and sexually transmitted diseases Sexually transmitted diseases Infections that are acquired and transmitted by sexual contact. Although virtually any infection may be transmitted during intimate contact, the term sexually transmitted disease is restricted to conditions that are largely , plans a major presence at the American College of Obstetricians and Gynecologists The American College of Obstetricians and Gynecologists (ACOG) is a professional association of medical doctors specializing in obstetrics and gynecology in the United States. It has a membership of over 49,000[1] and represents 90 percent of U.S. (ACOG ACOG American College of Obstetricians and Gynecologists. ACOG American College of Obstetricians & Gynecologists ) annual clinical meeting in New Orleans from May 3rd to May 7th. The company's plans for the annual clinical meeting include the official U.S. sales launch of the SoftPAP([R]) Collector. "The annual meeting of ACOG is the perfect place for the launch of our newly approved SoftPaP," said Robert McCullough, Jr., Chief Executive Officer of CytoCore. "ACOG is attended by the quintessential target audience of clinicians and physicians who would use the SoftPAP," added Mr. McCullough. As part of the national sales launch, CytoCore will unveil new informative sales tools including a video that includes both physician and patient testimonials, as well as a patient brochure explaining the benefits and comfort of the SoftPAP([R]) Collector. The company also plans to add these tools to their website, enabling physicians and patients to access the information. About CytoCore Inc. CytoCore develops cost-effective, highly accurate screening systems for early detection of gynecological cancers and sexually transmitted diseases. Designed for easy deployment at a laboratory or at the point-of-care, the CytoCore suite of sample collection technologies assists in the detection of cervical, endometrial endometrial /en·do·me·tri·al/ (en?do-me´tre-il) pertaining to the endometrium. endometrial, n relating to the end-ometrium or cavity of the uterus. , and other cancers, as well as the human Papilloma virus human papilloma virus n. Abbr. HPV A DNA virus of the genus Papillomavirus, certain types of which cause cutaneous and genital warts in humans, including condyloma acuminatum. . The CytoCore Solutions[TM] System is being developed to provide medical practitioners with highly accurate, low-cost, cervical and uterine cancer uterine cancer Malignant tumour of the uterus. Cancers affecting the lining of the uterus (endometrium) are the most common cancers of the female reproductive tract. screening systems that can be seamlessly integrated into existing medical models. More information is available at: www.CytoCoreInc.com. Certain statements in this release are forward-looking. These statements are based on CytoCore's current expectations and involve many risks and uncertainties, such as the company's inability to obtain sufficient financing, the possibility that clinical trials will not substantiate CytoCore's expectations with respect to the CytoCore Solutions[TM] System, and other factors set forth in reports and documents filed by CytoCore with the Securities and Exchange Commission. Actual results may differ materially from CytoCore's current expectation depending upon a number of factors affecting the Company's business. These factors include, among others, risks and uncertainties detailed in the Company's periodic public filings with the Securities and Exchange Commission, including but not limited to the Company's Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the year ended December 31, 2006. Except as expressly required by law, CytoCore undertakes no obligation to publicly update or revise any forward-looking statements contained herein. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion